Imakin 400 mg (Tablet)

Unit Price: ৳ 320.00 (3 x 10: ৳ 9,600.00)
Strip Price: ৳ 3,200.00

Medicine Details

Category Details
Generic Imatinib mesylate
Company Ziska pharmaceuticals ltd
Also available as
Imakin 100 mg tablet

Indications

  • Adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase
  • Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy
  • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
  • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
  • Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements
  • Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown
  • Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR a fusion kinase
  • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans
  • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
  • Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST

Pharmacology

  • Small molecule protein-tyrosine kinase inhibitor
  • Inhibits the activity of the Bcr-Abl tyrosine kinase, Kit, discoidin domain receptors (DDR1 and DDR2), CSF-1R, PDGFR-alpha, and PDGFR-beta
  • Well absorbed after oral administration with Cmax achieved within 2-4 hours post-dose
  • Mean absolute bioavailability is 98%
  • Metabolized by CYP3A4

Dosage & Administration

  • Adults with Ph+ CML CP: 400 mg/day
  • Adults with Ph+ CML AP or BC: 600 mg/day
  • Pediatrics with Ph+ CML CP: 340 mg/m2/day
  • Adults with Ph+ ALL: 600 mg/day
  • Pediatrics with Ph+ ALL: 340 mg/m2/day
  • Adults with MDS/MPD: 400 mg/day

Interaction

  • Concomitant administration with strong CYP3A4 inducers may reduce total exposure of imatinib
  • Concomitant administration with strong CYP3A4 inhibitors may result in a significant imatinib exposure increase
  • Imatinib will increase plasma concentration of CYP3A4 metabolized drugs

Side Effects

  • Fluid retention and edema
  • Hematologic toxicity
  • Congestive heart failure and left ventricular dysfunction
  • Hepatotoxicity
  • Hemorrhage
  • Gastrointestinal disorders
  • Hypereosinophilic cardiac toxicity
  • Dermatologic toxicities

Pregnancy & Lactation

  • Limited data on the use of imatinib in pregnant women
  • Spontaneous abortions and infant congenital anomalies reported
  • Potential risk for the fetus is unknown

Precautions & Warnings

  • Edema and severe fluid retention
  • Cytopenias, particularly anemia, neutropenia, and thrombocytopenia
  • Severe congestive heart failure and left ventricular dysfunction
  • Severe hepatotoxicity, including fatalities may occur
  • Grade 3/4 hemorrhage
  • Cardiogenic shock/left ventricular dysfunction
  • Bullous dermatologic reactions
  • Hypothyroidism

Overdose Effects

  • Reported outcome in overdose cases includes nausea, vomiting, rash, and thrombocytopenia
  • Experience with doses higher than the recommended therapeutic dose is limited

Therapeutic Class

  • Targeted Cancer Therapy
  • Tyrosine Kinase Inhibitor

Storage Conditions

  • Store below 30°C
  • In a cool and dry place
  • Keep away from light
  • Keep out of the reach of children

Related Brands